prikaz prve stranice dokumenta Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
  Preuzmi
PDF 377.01 KB
Znanstveni rad - Pregledni rad
Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
Cardiovascular Therapeutics, 2022 (2022); 8129513. https://doi.org/10.1155/2022/8129513
Merćep, Iveta; Friščić, Nikolina; Strikić, Dominik; Reiner, Željko

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Merćep, I., Friščić, N., Strikić, D. i Reiner, Ž. (2022). Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review. Cardiovascular Therapeutics, 2022.. doi: 10.1155/2022/8129513

Merćep, Iveta, et al. "Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review." Cardiovascular Therapeutics, vol. 2022, 2022. https://doi.org/10.1155/2022/8129513

Merćep, Iveta, Nikolina Friščić, Dominik Strikić i Željko Reiner. "Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review." Cardiovascular Therapeutics 2022 (2022). https://doi.org/10.1155/2022/8129513

Merćep, I., et al. (2022) 'Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review', Cardiovascular Therapeutics, 2022. doi: 10.1155/2022/8129513

Merćep I, Friščić N, Strikić D, Reiner Ž. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review. Cardiovascular Therapeutics [Internet]. 10.02.2022. [pristupljeno 12.05.2024.];2022. doi: 10.1155/2022/8129513

I. Merćep, N. Friščić, D. Strikić i Ž. Reiner, "Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review", Cardiovascular Therapeutics, vol. 2022, Veljača 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:539871. [Citirano: 12.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:539871
Podaci o radu
Naslov (engleski)Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
AutorIveta Merćep
AutorNikolina Friščić
AutorDominik Strikić
AutorŽeljko Reiner
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide. In contrast to conventional pharmacotherapy, human monoclonal antibodies directed against proprotein convertase subtilisin/kexin type 9 (PSCK9) and small interfering RNA- (siRNA-) based drug targeting PCSK9 represent a new strategy for managing lipid disorders and reducing cardiovascular risk. Inclisiran is a long-acting, synthetic siRNA that targets hepatic production of PCSK9 and consequently causes a reduction in LDL-C concentrations by approximately 50% compared to placebo. The structural modification of inclisiran has led to better stability and prolonged biological activity of the drug. The main advantage over conventional pharmacotherapy and anti-PCSK9 monoclonal antibodies is its favorable administration regimen (0–90–180 days), which should lead to much better compliance. Clinical trials conducted so far have confirmed the tolerability and efficacy of inclisiran in long-term PCSK9 and LDL-C level reductions. Moreover, a short-term follow-up on the safety of inclisiran showed a relatively good safety profile of the drug. However, it is still of great importance for ongoing and forthcoming clinical trials to be continued on a larger group of patients in order to assess long-term tolerability, efficacy, and safety of inclisiran.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCardiovascular Therapeutics
Brojčani podacivol. 2022, 8129513
p-ISSN1755-5914
e-ISSN1755-5922
DOIhttps://doi.org/10.1155/2022/8129513
URN:NBNurn:nbn:hr:105:539871
Datum objave publikacije2022-02-10
URL dokumentahttps://www.hindawi.com/journals/cdtp/2022/8129513/
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-10-10 09:10:05